Search

Displaying results 5171 - 5180 of 7600 in total
  1. Drug

    Uliledlimab

    go.drugbank.com/drugs/DB16675
    Investigational

    Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).

  2. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    It was investigated for melanoma.

  3. Drug

    Sarpogrelate

    go.drugbank.com/drugs/DB12163
    Investigational

    Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

  4. Drug

    HH-009

    go.drugbank.com/drugs/DB18727
    Investigational

    HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.

  5. Drug

    TBI-223

    go.drugbank.com/drugs/DB18911
    Investigational

    TBI-223 is under investigation in clinical trial NCT06192160 (Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis).

  6. Drug

    Ginsenoside Rd

    go.drugbank.com/drugs/DB19256
    Investigational

    Ginsenoside Rd is under investigation in clinical trial NCT00815763 (Efficacy and Safety of Ginsenoside-rd for Acute Ischemic Stroke).

  7. Drug

    Ovatodiolide

    go.drugbank.com/drugs/DB19264
    Investigational

    Ovatodiolide is under investigation in clinical trial NCT04220411 (A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)).

  8. Drug

    Rovadicitinib

    go.drugbank.com/drugs/DB21747
    Investigational

    Rovadicitinib is under investigation in clinical trials NCT06682169 and NCT06300320 for the treatment of Chronic Graft-versus-host Disease.

  9. Drug

    Beclabuvir

    go.drugbank.com/drugs/DB12225
    Investigational

    Beclabuvir has been used in trials studying the treatment of Hepatitis C, Chronic.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.